This information is intended for Vermont Prescribers.
33 V.S.A. § 2005a.
| Product Name | Short Form | Long Form | Date updated |
|---|---|---|---|
| Aubagio® (teriflunomide) | Aubagio Short Form | Aubagio Long Form | January 20, 2020 |
| Avalide® (irbesartan and hydrochlorothiazide) | Avalide Short Form | Avalide Long Form | January 20, 2020 |
| Avapro® (irbesartan) | Avapro Short Form | Avapro Long Form | January 20, 2020 |
| Cerdelga (eliglustat) | Cerdelga Short Form | Cerdelga Long Form | January 20, 2020 |
| Multaq (dronedarone) | Multaq Short Form | Multaq Long Form | January 20, 2020 |
| Renvela (sevelamer carbonate) | Renvela Short Form | Renvela Long Form | January 20, 2020 |
| Caprelsa (vandetanib) | Caprelsa Short Form | Caprelsa Long Form | January 20, 2020 |
Guide to Vermont's Pharmaceutical Marketer Price Disclosure Law, 33 V.S.A. § 2005a. Published by the Vermont Office of the Attorney General.
Please See Full Prescribing Information, including Boxed Warning, for Avalide, Avapro, Aubagio, Caprelsa and Multaq.